Clinical predictors of survival in real world practice in stage <scp>IV</scp> melanoma-Reference-Cited by-同舟云学术

Clinical predictors of survival in real world practice in stage IV melanoma

Published:2022-09-25 Issue:2 Volume:6 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Hu Hsien‐Pang¹^ORCID,Archer Christine²³^ORCID,Yip Desmond¹²^ORCID,Peters Geoffrey¹²^ORCID

Affiliation:

1. ANU Medical School Australian National University Canberra Australia

2. Department of Medical Oncology The Canberra Hospital Canberra Australia

3. College of Nursing & Health Sciences Flinders University Adelaide South Australia Australia

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1691

Reference48 articles.

1. Prolonged survival of 2 years or longer for patients with disseminated melanoma

2. Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?

3. Promising pre‐clinical validation of targeted radionuclide therapy using a [131i] labelled iodoquinoxaline derivative for an effective melanoma treatment;Bonnet‐Duquennoy M;J Cancer Sci Ther,2009

4. LongG KeffordR McArthurG MatteoC MenziesA.Targeted therapies for melanoma Cancer Council Australia Melanoma Guidelines Working Party 2019.https://wiki.cancer.org.au/australiawiki/index.php?oldid=199444.

5. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Observational Multi-center Study: Retrospective Analysis of Diagnostic and Treatment Patterns for Stage III–IV Melanoma in Ukraine from 2018 to 2020;Open Access Macedonian Journal of Medical Sciences;2024-03-20

2. The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma;Cancers;2024-03-04